Renaud Jacquemart

Omnium Global is a Canadian Venture Studio focused on building and scaling high-impact biotechnology companies through a deeply hands-on, execution-driven model. Rather than acting as a traditional investor, Omnium partners closely with founders by deploying not only capital, but also leadership and operational expertise to transform early-stage scientific ideas into fundable, scalable ventures. The team works side-by-side with companies—often stepping in as fractional executives—to develop strategy, advance product development, and guide critical milestones such as preclinical work, regulatory readiness, and early clinical studies. Through our extensive global network of industry leaders, investors, and technical experts, we unlock opportunities, accelerate development, and optimize outcomes for every venture we support. The venture studio targets opportunities at the intersection of science, execution, and commercialization, with a focus on areas such as drug delivery platforms, vaccines and infectious disease technologies, AI-enabled biotech tools, advanced biomanufacturing systems, and low-cost biologics aimed at improving global access. Beyond funding, Omnium Ventures provides comprehensive company-building infrastructure, supporting governance, intellectual property strategy, CMC and regulatory pathways, and partnering strategies. It also leverages a global network of investors, CDMOs, scientific experts, and pharmaceutical partners to accelerate development and unlock opportunities that early-stage companies may not be able to access independently. Overall, Omnium positions itself as a “true partner in execution,” co-building companies with founders to increase their probability of success and bring innovative biotechnologies to market more effectively.